title: [A study of the efficacy and safety of using hepatitis B surface antigen-positive donors for liver transplantation].
abstract: OBJECTIVE
  To evaluate the outcomes of liver transplant recipients who received liver allografts from hepatitis B surface antigen (HBsAg)-positive donors.
  
  
  METHODS
  The medical records of 23 male patients (median age, 42.5 years; range: 29-61) who received HBsAg-(+) liver allografts in our organ transplant center were retrospectively analyzed. All patients had confirmed diagnosis of end-stage liver disease (ESLD) secondary to hepatitis B virus (HBV) infection, including 13 HBsAg(+)/HBeAg(-)/HBcAb(+) cases and 10 HBsAg(+)/HBeAb(+)/HBcAb(+) cases. After transplantation, all patients were administered oral entecavir and intravenous anti-hepatitis B immunoglobulin (HBIG) (2000 IU/d during the first week), along with a steroid-free immune suppression regimen. HBV-related antigen and antibody and HBV DNA were detected on post-transplantation days 1, 7, 14, 21, and 30. The liver allografts were monitored by ultrasound imaging. After discharge, monthly follow-up recorded liver function, renal function, acute rejection, infections, vascular complications, biliary complications, HBV recurrence, cancer recurrence, and patient survival.
  
  
  RESULTS
  Two of the recipients died from severe perioperative pneumonia. The remaining 21 recipients were followed-up for 10 to 38 months, and all 21 patients remained HBsAg(+). One recipient developed biliary ischemia and required a second liver transplantation at five months after the primary transplantation. Three recipients (all primary) died from tumor recurrence at 9, 14, and 18 months post-transplantation, respectively. All other recipients survived and had acceptably low HBV DNA copy levels. Color Doppler imaging showed good graft function and normal texture. The patient and graft survival rates were 78.3% (18/23) and 73.9% (17/23), respectively. The recurrence rate of HBV infection was 100% (23/23). In surviving patients, no liver function abnormality, graft loss, or death was found to be related to the recurrence of HBV infection.
  
  
  CONCLUSIONS
  Liver transplantation using HBsAg(+) liver grafts was safe for patients with ESLD secondary to HBV infection.
authors.affiliation: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
authors.forename: Wei-qiang
authors.initials: WQ
authors.lastname: Ju
authors.forename: Xiao-shun
authors.initials: XS
authors.lastname: He
authors.forename: Dong-ping
authors.initials: DP
authors.lastname: Wang
authors.forename: Rong-hai
authors.initials: RH
authors.lastname: Deng
authors.forename: Lin-wei
authors.initials: LW
authors.lastname: Wu
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Guo
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Zhu
authors.forename: Jie-fu
authors.initials: JF
authors.lastname: Huang
mesh_terms: D000328:Adult; D058625:End Stage Liver Disease / Q000601:surgery* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology* / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D006514:Hepatitis B Surface Antigens